Dost-Kovalsky Karen, Thiel Sandra, Ciplea Andrea I, Gold Ralf, Hellwig Kerstin
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstraße 56, 44791 Bochum, Germany.
Mult Scler. 2023 Mar;29(3):461-465. doi: 10.1177/13524585221131486. Epub 2022 Oct 22.
As cladribine is contraindicated in pregnancy, data to pregnancy outcomes and disease control are scarce.
To investigate the effects of Cladribine use, in the last 6 months prior (56.4%) to or after (43.6%) the last menstrual period in a population of women with multiple sclerosis, on pregnancy outcomes and relapse rate during pregnancy and postpartum.
Data were collected prospectively in regular telephone interviews.
Of 39 pregnancies, 27 babies have been born so far and one major congenital malformation occurred. Disease control was excellent among the cohort both during pregnancy and the postpartum period, with only one relapse recorded in each time period.
Although most newborns are healthy, reinforced councelling on effective contraception 6 months after the last cladribine dosing is necessary.
由于克拉屈滨在孕期禁用，关于其对妊娠结局及疾病控制的数据稀缺。
调查在患有多发性硬化症的女性群体中，于末次月经前（56.4%）或末次月经后（43.6%）的最后6个月使用克拉屈滨，对妊娠结局以及孕期和产后复发率的影响。
通过定期电话访谈前瞻性收集数据。
在39次妊娠中，目前已出生27名婴儿，发生了1例严重先天性畸形。该队列在孕期和产后疾病控制良好，每个时间段仅记录到1次复发。
尽管大多数新生儿健康，但末次使用克拉屈滨6个月后仍需加强有效的避孕咨询。
Zotero 插件